BG63122B1 - Съединения и методи за лечение на рак - Google Patents

Съединения и методи за лечение на рак

Info

Publication number
BG63122B1
BG63122B1 BG101284A BG10128497A BG63122B1 BG 63122 B1 BG63122 B1 BG 63122B1 BG 101284 A BG101284 A BG 101284A BG 10128497 A BG10128497 A BG 10128497A BG 63122 B1 BG63122 B1 BG 63122B1
Authority
BG
Bulgaria
Prior art keywords
cancer
compounds
methods
oddc
dioxolan
Prior art date
Application number
BG101284A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101284A (bg
Inventor
Chung Chu
Yung-Chi Cheng
Original Assignee
Yale University
University Of Georgia Research Foundation,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Yale University, University Of Georgia Research Foundation,Inc. filed Critical Yale University
Publication of BG101284A publication Critical patent/BG101284A/xx
Publication of BG63122B1 publication Critical patent/BG63122B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
BG101284A 1994-09-06 1997-03-05 Съединения и методи за лечение на рак BG63122B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (fr) 1994-09-06 1995-09-05 Composes et procedes de traitement du cancer

Publications (2)

Publication Number Publication Date
BG101284A BG101284A (bg) 1998-03-31
BG63122B1 true BG63122B1 (bg) 2001-04-30

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101284A BG63122B1 (bg) 1994-09-06 1997-03-05 Съединения и методи за лечение на рак

Country Status (31)

Country Link
US (3) US6063787A (fr)
EP (2) EP1468687A1 (fr)
JP (1) JP3979662B2 (fr)
KR (1) KR100374477B1 (fr)
CN (3) CN1827108A (fr)
AP (1) AP783A (fr)
AT (1) ATE267015T1 (fr)
AU (1) AU704977B2 (fr)
BG (1) BG63122B1 (fr)
BR (1) BR9508886A (fr)
CA (1) CA2199117C (fr)
CZ (1) CZ297873B6 (fr)
DE (1) DE69533066T2 (fr)
DK (1) DK0781136T3 (fr)
ES (1) ES2219666T3 (fr)
FI (1) FI970918L (fr)
HU (1) HUT77172A (fr)
IL (1) IL115156A (fr)
IS (1) IS2011B (fr)
MY (1) MY121548A (fr)
NO (1) NO313268B1 (fr)
NZ (1) NZ335013A (fr)
OA (1) OA10473A (fr)
PL (2) PL188359B1 (fr)
PT (1) PT781136E (fr)
RO (1) RO118748B1 (fr)
RU (1) RU2168995C2 (fr)
SI (1) SI0781136T1 (fr)
SK (1) SK284564B6 (fr)
WO (1) WO1996007413A1 (fr)
ZA (1) ZA957483B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
ATE413881T1 (de) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
DE60042921D1 (de) * 1999-03-29 2009-10-22 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
WO2001022950A2 (fr) 1999-09-24 2001-04-05 Shire Biochem Inc. Methode de traitement ou de prevention d'infections virales au moyen d'analogues nucleosidiques
CA2389745C (fr) 1999-11-04 2010-03-23 Shire Biochem Inc. Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
EP1600452A3 (fr) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthèse de 2'-déoxy-L-nucléosides
CN100376570C (zh) * 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
WO2002056832A2 (fr) 2001-01-19 2002-07-25 Newbiotics, Inc. Procedes relatifs au traitement des maladies auto-immunes et inflammatoires
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
AU2002242561A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
CA2465682A1 (fr) * 2001-11-02 2003-05-08 Shire Biochem Inc. Methodes pour le traitement de la leucemie
EP2055300B1 (fr) * 2001-11-19 2016-01-27 Medigene AG Médicament comprenant du myristate d'isopropyle et une catéchine
CN1556988B (zh) 2002-06-21 2011-09-14 Lg电子株式会社 具有用于管理记录在其上面的视频数据的再现的数据结构的记录介质
CA2465105C (fr) 2002-06-21 2012-08-28 Lg Electronics Inc. Support d'enregistrement comprenant une structure de donnees pour gerer la reproduction des donnees video enregistrees sur ce support d'enregistrement
WO2004001750A1 (fr) 2002-06-24 2003-12-31 Lg Electronics Inc. Support d'enregistrement comportant une structure de donnees pour la gestion de la reproduction de donnees video a voies de reproduction multiples qui y sont enregistrees et procedes et appareils d'enregistrement et de reproduction
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
EP1518240B1 (fr) 2002-06-28 2014-05-07 LG Electronics, Inc. Support d'enregistrement comportant une structure de donnees permettant la gestion de l'enregistrement et de la lecture de donnees de trajets multiples enregistrees sur ledit support et procedes et appareil d'enregistrement et de lecture
CN100372535C (zh) * 2002-09-24 2008-03-05 诺瓦提斯公司 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
EP1552519A4 (fr) 2002-10-14 2006-08-16 Lg Electronics Inc Support d'enregistrement presentant une structure de donnees pour gerer la reproduction de flux audio multiples enregistres sur celui-ci et procedes et appareils d'enregistrement et de reproduction
WO2004036578A1 (fr) 2002-10-15 2004-04-29 Lg Electronics Inc. Support d'enregistrement presentant une structure de donnees pour gerer la reproduction de flux graphiques multiples enregistres sur celui-ci et procedes et appareils d'enregistrement et de reproduction
RU2313139C2 (ru) 2002-11-12 2007-12-20 Эл Джи Электроникс Инк. Носитель записи со структурой данных для управления воспроизведением записанных на нем видеоданных нескольких каналов воспроизведения и способы и устройства записи и воспроизведения
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7606463B2 (en) 2003-02-24 2009-10-20 Lg Electronics, Inc. Recording medium having data structure for managing playback control and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
CN100397882C (zh) 2003-02-28 2008-06-25 Lg电子株式会社 具有用于管理记录其上的视频数据的随机/洗牌重现的数据结构的记录媒体以及记录和重现的方法和装置
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
WO2005037300A1 (fr) 2003-10-09 2005-04-28 Medigene Ag Utilisation d'un polyphenol pour le traitement d'une lesion cancereuse ou precancereuse de la peau
BRPI0613796A2 (pt) * 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
CN101511375B (zh) * 2005-12-02 2012-09-05 耶鲁大学 L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
WO2008030373A2 (fr) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. Promédicaments l- oddc pour le cancer
RU2322243C1 (ru) * 2006-10-20 2008-04-20 Наталья Юрьевна Костюкова Фармацевтическая композиция для лечения поражений роговицы
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CA3045228C (fr) * 2016-12-28 2024-01-02 Transgene Sa Virus oncolytiques et molecules therapeutiques
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
WO1987001284A1 (fr) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition du caractere infectieux et de l'effet cytopathique du htlv-iii/lav in vitro par la 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, ou 2',3'-dideoxyadenosine
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (fr) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
ATE108183T1 (de) * 1987-03-24 1994-07-15 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (fr) * 1991-03-06 2003-10-28 George Robert Painter Iii Nucleosides therapeutiques
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5811538A (en) * 1993-12-30 1998-09-22 Genta, Incorporated Process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
CZ63397A3 (en) 1997-07-16
RO118748B1 (ro) 2003-10-30
NO971015L (no) 1997-03-05
ES2219666T3 (es) 2004-12-01
AU704977B2 (en) 1999-05-13
DE69533066T2 (de) 2005-06-02
PL188359B1 (pl) 2005-01-31
CA2199117C (fr) 2006-04-11
SK28197A3 (en) 1997-09-10
US20050261320A1 (en) 2005-11-24
CA2199117A1 (fr) 1996-03-14
FI970918A7 (fi) 1997-05-02
CN1827108A (zh) 2006-09-06
IS4434A (is) 1997-03-04
IL115156A (en) 2000-07-16
KR100374477B1 (ko) 2003-06-19
CN1111409C (zh) 2003-06-18
PL189288B1 (pl) 2005-07-29
HUT77172A (hu) 1998-03-02
FI970918A0 (fi) 1997-03-04
SI0781136T1 (en) 2004-08-31
CN1251680C (zh) 2006-04-19
DE69533066D1 (de) 2004-06-24
MY121548A (en) 2006-02-28
RU2168995C2 (ru) 2001-06-20
OA10473A (en) 2002-04-08
NO313268B1 (no) 2002-09-09
AU3586295A (en) 1996-03-27
US6063787A (en) 2000-05-16
IS2011B (is) 2005-05-13
IL115156A0 (en) 1995-12-31
KR970705393A (ko) 1997-10-09
EP0781136B1 (fr) 2004-05-19
ATE267015T1 (de) 2004-06-15
US20080171758A1 (en) 2008-07-17
EP1468687A1 (fr) 2004-10-20
CN1448142A (zh) 2003-10-15
NO971015D0 (no) 1997-03-05
EP0781136A4 (fr) 1999-06-23
PT781136E (pt) 2004-09-30
AP9700939A0 (en) 1997-04-30
FI970918L (fi) 1997-05-02
NZ335013A (en) 2000-07-28
US7262213B2 (en) 2007-08-28
AP783A (en) 1999-11-17
SK284564B6 (sk) 2005-06-02
DK0781136T3 (da) 2004-08-02
US8076347B2 (en) 2011-12-13
CZ297873B6 (cs) 2007-04-18
CN1160351A (zh) 1997-09-24
EP0781136A1 (fr) 1997-07-02
ZA957483B (en) 1997-06-06
WO1996007413A1 (fr) 1996-03-14
BR9508886A (pt) 1997-12-30
JPH10506385A (ja) 1998-06-23
PL318971A1 (en) 1997-07-21
BG101284A (bg) 1998-03-31
JP3979662B2 (ja) 2007-09-19

Similar Documents

Publication Publication Date Title
BG101284A (bg) Съединения и методи за лечение на рак
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
ATE238307T1 (de) Substituierte porphyrinen
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
ES2155601T3 (es) Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
DK0971922T3 (da) Tetrahydropyrido-forbindelser
PT841912E (pt) 2-aminocarbonil-1,2-bis(metilsulfonil)-1-(substituido)-hidrazinas antitumor
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
DK0804465T3 (da) Nye elastaseinhibitorer
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
BR0012921A (pt) Compostos calcilìticos
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии